Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Requirements for High-Risk Drug Premium Explained by Korosho
March 22, 2010
- New Premium for Development of New Drugs “Poison Bait”
March 22, 2010
- Shionogi to Comarket Quick Chaser Flu A, B with Mizuho Medy
March 22, 2010
- Santen Files NDA for Higher-Concentration Levofloxacin
March 22, 2010
- Leading Generics-Only Companies'Foothold Undermined by Entry of Big Pharmas
March 22, 2010
- CDFS's Dept. on Drugs to Review Rozerem, DE-089, Soliris
March 22, 2010
- ¥105 Bil. Sales of Aricept to Be Lost in 3 Years Following Patent Expiration in the US
March 22, 2010
- 5-Day Dosing Regimen Approved for Dacogen in the US: Eisai
March 22, 2010
- Hope and Challenges for Personalized Medicine Highlighted
March 22, 2010
- Sato to Launch OTC Version of Troxipide
March 22, 2010
- Roche Suspends Development of Ocrelizumab Due to Adverse Reactions
March 22, 2010
- J-CLEAR Created for Objective Assessment of Data from Clinical Studies
March 22, 2010
- Gov't Should More Strongly Support Pharma Industry: Dr Teshirogi
March 22, 2010
- Merck to More Actively Tie Up with Others in Early Development Stage
March 22, 2010
- EFPIA Japan to Work to Eliminate Drug Lag
March 15, 2010
- Astellas Withdraws Application for Diabetic Incipient Nephropathy for Micardis
March 15, 2010
- Teijin Licenses SB623 from SanBio
March 15, 2010
- Korosho to Prepare for 2nd Round of Screening by GRU
March 15, 2010
- 2009 Sales of Ethical Drugs Up 7.2% to ¥8,851.6 Bil.: IMS Japan
March 15, 2010
- Takeda to Initiate PIII Trials for Lu AA21004, Lu AA24530 in the US
March 15, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…